NHS Supply Chain chooses Elekta to upgrade UK’s radiotherapy resources

CRAWLEY, UK, May 12, 2016 – The UK’s NHS Supply Chain (NHSSC) has signed an order to acquire linear accelerators (linacs) and software from Elekta (EKTA-B.ST) for a total value of GBP 21.5 million. The order was booked in the fourth quarter of Elekta’s fiscal year (2015-16).

The order includes Elekta Synergy® linacs with Agility™ multileaf collimators for high speed beam shaping. The Synergy linacs also include VMAT, which improves radiation therapy treatment speed and dose reduction to the patient.

Andy Brown, Managing Director of NHS Supply Chain Capital Solutions, says: “The Capital Team supports patient care by delivering the latest equipment at the best value. These systems are a key part of delivering world class cancer care and by using the Department of Health’s Capital Equipment fund to support the bulk procurement with Elekta Ltd, we have released greater value for trusts and savings back to the NHS.”

François Pointurier, Senior Vice President, Region Europe and AFLAME at Elekta says: “This order comes on the tail of a recent study in the Green Journal (Radiotherapy & Oncology) titled ‘Radiotherapy in Europe: An unmet need?’ Elekta is delighted to be part of the solution by supporting the NHS in their investment to address this situation and help improve the lives of patients with cancer in the UK.”

Paddy Greally, Elekta’s Managing Director for the UK and Ireland, says: “Elekta is delighted to continue our relationship with NHSSC and our long-term commitment to radiotherapy in the UK. We are especially proud to deliver this equipment to treat cancer from our international linac manufacturing site in Crawley.”

All equipment and software will be delivered over the next 24 months.

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time

Tobias Bülow, Director Financial Communication, Elekta AB
Tel: +46 722 215 017, e-mail: tobias.bulow@elekta.com 
Time zone: CET: Central European Time

The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on May 12, 2016.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com.

Tags:

About Us

Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com

Subscribe

Documents & Links